Publique un comentario 
Desafíos en el empleo de los medicamentos huérfanos
Texto completo:
PDFResumen
Palabras clave
Referencias
Abozaid GM, Kerr K, Mcknight A, Al-Omar HA. Criteria to define rare diseases and orphan drugs: a systematic review protocol. BMJ Open [Internet]. 2022 [cited 24/12/2022];12(7):62126. Available from: https://pureadmin.qub.ac.uk/ws/portalfiles/portal/379545026/Orphan.pdf
Quirland-Lazo C, Castañeda-Cardona C, Chirveches Calvache MA, Aroca A, Otálora Esteban M, Rosselli D. Modelos de atención en salud en enfermedades raras: revisión sistemática de la literatura. Rev Gerenc y Polít Salud [Internet]. 2018 [citado 02/01/2023];17(34):1-7. Disponible en: http://www.scielo.org.co/pdf/rgps/v17n34/1657-7027-rgps-17-34-00112.pdf
Henry D, Lexchin J. The pharmaceutical industry as a medicines provider. The Lancet. [Internet]. 2002. [cited 02/01/2023]; 360(9345):1590-1595. Available from: https://www.sciencedirect.com/science/article/pii/S0140673602115273
U.S. Food and Drug Administration. [Internet]. U.S.A: US Department of Health and Human Services; c2018-23 [up-date 13/12/2022 cited 24/12/2022]. Rare Diseases at FDA; [aprox. 2 screen]. Available from: https://www.fda.gov/patients/rare-diseases-fda
Gobierno de México [Internet]. México: Secretaría de Salud; 2019 [actualizado 01/03/2019; citado 24/12/2022]. ¿Qué son las enfermedades raras?; [aprox. 2 pantallas]. Disponible en: https://www.gob.mx/salud/articulos/que-son-las-enfermedades-raras-193280
Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? HHS Public Access. Nat Rev Drug Discov [Internet]. 2020 [cited 25/12/2022];19(2):77–78. Available from: https://www.nature.com/articles/d41573-019-00180-y
Vicente E, Pruneda L, Ardanaz E. Paradoja de la rareza: a propósito del porcentaje de población afectada por enfermedades raras. Gac Sanit [Internet]. 2020 [citado 02/01/2023];34(6):536–538. Disponible en: https://www.gacetasanitaria.org/es-pdf-S0213911120300753
McNeilly EK. Designating an Orphan Product: Drug and Biological Products-Orphan Drug Regulations: Regulatory History. [Internet]. 2014 [citado 09/02/2023];283745. Disponible en: https://www.fda.gov/industry/medical- products-rare-diseases-and-conditions/designating-orphan-product-drugs-and- biological-products
U.S. Food and Drug Administration. [Internet]. U.S.A: US Department of Health and Human Services; c2018-23 [up-date 13/12/2022 cited 24/12/2022]. The Story Behind the Orphan Drug Act; [aprox. 2 screen]. Available from: https://www.fda.gov/industry/fdas-rare-disease-day/story-behind-orphan-drug-act
Aranda M, Rosasco MA, Aranda M, Rosasco MA. La farmacia de los medicamentos genéricos. Rev Colomb Ciencias Químico-Farm [Internet]. 2019 [citado 09/02/2023];48(2):357–371. Disponible en: http://www.scielo.org.co/pdf/rccqf/v48n2/0034-7418-rccqf-48-02-357.pdf
Ferreira CR. The burden of rare diseases. Am J Med Genet [Internet]. 2019 [cited 03/01/2023]; 179(6), 885-892. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajmg.a.61124
Fontanet Sacristán JM, Torrent-Farnell J. Orphan drugs. Arbor [Internet]. 2018 [cited 03/01/2023];194(789):a466. Available from: https://arbor.revistas.csic.es/index.php/arbor/article/view/2279/3238
Deore AB, Dhumane JR, Wagh R, Sonawane R. The Stages of Drug Discovery and Development Process. Asian J Pharm Res Dev. [Internet]. 2019 [cited 03/01/2023];7(6):62–67. Available from: https://www.ajprd.com/index.php/journal/article/view/616
Fonseca DA, Amaral I, Pinto AC, Cotrim MD. Orphan drugs: major development challenges at the clinical stage. Drug Discov Today. [Internet]. 2019 [cited 03/01/2023];24(3):867–872. Available from: https://pubmed.ncbi.nlm.nih.gov/30658132/
Lanar S, Acquadro C, Seaton J, Savre I, Arnould B. To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases. Orphanet Journal of Rare Diseases. [Internet]. 2020 [cited 05/01/2023];15(1)1–18. Available from: https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01400-0
Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol [Internet]. 2011 [cited 04/01/2023];71(4):488–496. Available from: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/j.1365- 2125.2010.03877.x
Leache L, Saiz LC, Gutiérrez-Valencia M, Erviti J. Orphan drugs, incentives and uncertainty about their risk-benefit balance. Gac Sanit. [Internet]. 2021 [cited 05/01/2023];35(2)208–9. Available from: https://doi.org/10.1016/j.gaceta.2020.05.012
Olajide SE, Lizam M, Olajide EB. Understanding The Conceptual Definitions of Cost, Price, Worth and Value. IOSR J Humanit Soc Sci. [Internet]. 2016 [cited 05/01/2023];21(09):53–57. Available from: https://www.iosrjournals.org/iosr- jhss/papers/Vol.%2021%20Issue9/Version-1/I2109015357.pdf
Iecovich E, Carmel S. Differences in Accessibility, Affordability, and Availability (AAA) of Medical Specialists Among Three Age-Groups of Elderly People in Israel. Journal of aging and health [Internet]. 2009 [cited 04/01/2023];21(5). Available from: https://journals.sagepub.com/doi/pdf/10.1177/0898264309333322?casa_token=Ls GkU_YaLtUAAAAA:2kfSiaH99ukzPiyjHc- pHLgGnCzZdnUV2rzF7g9OHAYmNc6FAnN6PFDNFMZSRuLH4agZvAU8YYZaf Q
Weerasooriya SU. The impact of orphan drug policies in treating rare diseases. Health Info Libr J [Internet]. 2019 [cited 04/01/2023];36(2):179–84. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/hir.12256
Chan A, Chan V, Olsson S, Fan M, Jit M, Health MG-V in, et al. Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis. Value in Health [Internet]. 2020 [cited 09/02/2023];23(12):1580- 1591. Available from: https://www.sciencedirect.com/science/article/pii/S1098301520344132
Lexchin J, Moroz N. Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia. International Journal of Health Services [Internet]. 2020 [cited 04/01/2023]; 50(2):166-172. Available from: https://journals.sagepub.com/doi/10.1177/0020731419886526?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Wang X, Li S-C, Yue X, Li Y, Shi N, Zhao F-L, et al. Patient Access to Medical Insurance Covered Orphan Drugs in China: Real-World Evidence From Patient Survey. Value Heal Reg Issues [Internet]. 2023 [cited 04/01/2023];34:71–77. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2212109922001959
Qiao L, Liu X, Shang J, Zuo W, Xu T, Qu J, et al. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges. Orphanet J Rare Dis [Internet]. 2022 [cited 04/01/2023];17(1):1–12. Available from: https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02507- 2
Merlini G, Gribben J, Macintyre E, Piggin M, Doeswijk R. Access to Affordable Orphan Medicines in Europe: An EHA Position Paper. HemaSphere [Internet]. 2020 [cited 04/01/2023];4(5):e477. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544271/pdf/hs9-4-e477.pdf
Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis [Internet]. 2019 [cited 04/01/2023];14(1):1–10. Available from: https://link.springer.com/articles/10.1186/s13023-018-0990-4
Haycox A, Noble E. What is health economics? Hayward Medical Communications. [Internet]. 2009 [cited 04/01/2023];1–8. Available from: http://www.bandolier.org.uk/painres/download/whatis/What_is_health_econ.pdf
Goldstein DA. Using quality-adjusted life-years in cost-effectiveness analyses: do not throw out the baby or the bathwater. Journal of Oncology Practice [Internet]. 2016 [cited 09/02/2023];12(6):500–502. Available from: https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2016.011460
Bakker CH, Rutten-van Mölken M, van Doorslaer E, Bennett K, van der Linden S. Health related utility measurement in rheumatology: an introduction. Patient Educ Couns. [Internet] 1993 [cited 09/02/2023];20(2–3):145–152. Available from: https://doi.org/10.1016/0738-3991(93)90128-J
Prieto L, Sacristán JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes [Internet]. 2003 [cited 04/01/2023];1:80. Available from: https://doi.org/10.1186/1477-7525-1-80
Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc [Internet]. 2020 [cited 04/01/2023];18(1):1–18. Available from: https://doi.org/10.1186/s12962-020-00223-x
Harari S. Why we should care about ultra-rare disease. Eur Respir Soc [Internet]. 2016 [cited 10/01/2023];25(140):101-103. Available from: https://err.ersjournals.com/content/errev/25/140/101.full.pdf
Chambers JD, Silver MC, Berklein FC, Cohen JT, Neumann PJ. Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non- orphan Drugs. J Gen Intern Med [Internet]. 2020 [cited 04/01/2023];35(9):2629– 2665. Available from: https://doi.org/10.1007/s11606-020-05805-2
Shahrubudin N, Lee TC, Ramlan R. An Overview on 3D Printing Technology: Technological, Materials, and Applications. Procedia Manuf. [Internet]. 2019 [cited 04/01/2023];35:1286–1296. Available from: https://doi.org/10.1016/j.promfg.2019.06.089
Yan Q, Dong H, Su J, Han J, Song B, Wei Q, et al. A Review of 3D Printing Technology for Medical Applications. Engineering. [Internet]. 2018 [cited 04/01/2023];4(5):729–742. Available from: https://doi.org/10.1016/j.eng.2018.07.021
Prasad LK, Smyth H. 3D Printing technologies for drug delivery: a review. Drug Dev Ind Pharm [Internet]. 2016 [cited 25/12/2022];42(7):1019–1031. Available from: https://pubmed.ncbi.nlm.nih.gov/26625986/
Afsana Jain V, Haider N, Jain K. 3D Printing in Personalized Drug Delivery. Curr Pharm Des. [Internet]. 2019 [cited 25/12/2022];24(42):5062–5071. Available from: http://www.eurekaselect.com/article/96689
Mohammed AA, Algahtani MS, Ahmad MZ, Ahmad J, Kotta S. 3D Printing in medicine: Technology overview and drug delivery applications. Ann 3D Print Med. [Internet]. 2021 [cited 25/12/2022];4(1-2):100037. Available from: https://www.researchgate.net/publication/356348558_3D_Printing_in_Medicine_Technology_Overview_and_Drug_Delivery_Applications
Liang K, Brambilla D, Leroux J-C, Liang K, Brambilla D, Leroux J-C. Is 3D Printing of Pharmaceuticals a Disruptor or Enabler? Adv Mater [Internet]. 2019 [cited 25/12/2022];31(5):1805680. Available from: https://doi.org/10.1002/adma.201805680
Beer N, Kaae S, Genina N, Sporrong SK, Alves TL, Hoebert J, et al. Magistral Compounding with 3D Printing: A Promising Way to Achieve Personalized Medicine. Ther Innov Regul Sci [Internet]. 2023 [cited 08/01/2023];57:26–36. Available from: https://doi.org/10.1007/s43441-022-00436-7
Vanhoorne V, Peeters E, Van Tongelen I, Boussery K, Wynendaele E, De Spiegeleer B, et al. Pharmaceutical compounding of orphan active ingredients in Belgium: How community and hospital pharmacists can address the needs of patients with rare diseases. Orphanet J Rare Dis [Internet]. 2019 [cited 08/01/2023];14(1). Available from: https://doi.org/10.1186/s13023-019-1154-x
Ceballos M, Giraldo JA, Marín VH, Amariles P. Caracterización de aspectos relacionados con la utilización de los medicamentos fiscalizados en droguerías y farmacias-droguerías de Medellín y el Área Metropolitana. Rev. Univ. Ind. Santander. Salud [Internet]. 2018 [citado 08/01/2023];50(1):27–36. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-08072018000100027
Gaikwad SS, Kshirsagar SJ. Review on Tablet in Tablet techniques. Beni-Suef Univ J Basic Appl Sci [Internet]. 2020 [cited 08/01/2023];9:1–7. Available from: https://doi.org/10.1186/s43088-019-0027-7
Nober C, Manini G, Carlier E, Raquez JM, Benali S, Dubois P, et al. Feasibility study into the potential use of fused-deposition modeling to manufacture 3D- printed enteric capsules in compounding pharmacies. Int J Pharm. [Internet]. 2019 [cited 08/01/2023];569. Available from: https://doi.org/10.1016/j.ijpharm.2019.118581
Andreadis LI, Gioumouxouzis CI, Eleftheriadis GK, Fatouros DG. The Advent of a New Era in Digital Healthcare: A Role for 3D Printing Technologies in Drug Manufacturing? Pharmaceutics [Internet]. 2022 [cited 08/01/2023];14(3). Available from: https://www.mdpi.com/1999-4923/14/3/609/htm
Saydam M, Takka S. Improving the dissolution of a water-insoluble orphan drug through a fused deposition modelling 3-Dimensional printing technology approach. Eur J Pharm Sci. [Internet]. 2020 [cited 08/01/2023];152:105426. Available from: https://doi.org/10.1016/j.ejps.2020.105426
Pharmaceutical Technology Editors. Aprecia and Cycle will develop 3D printed orphan drugs [Internet]. República Dominicana: Pharmatech; 2017 [cited 25/12/2022]. Available from: https://www.pharmtech.com/view/aprecia-pharmaceuticals-and-cycle-pharmaceuticals-partner-develop-3d-printed-orphan-drugs
Alves VM, Korn D, Pervitsky V, Thieme A, Capuzzi SJ, Baker N, et al. Knowledge- based approaches to drug discovery for rare diseases. Drug Discov Today. [Internet]. 2022 [cited 25/12/2022];27(2):490–502. Available from: https://doi.org/10.1016/j.drudis.2021.10.014
Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Drug Repurposing for Rare Diseases. Trends Pharmacol Sci. [Internet]. 2021 [cited 25/12/2022];42(4):255-67. Available from: https://doi.org/10.1016/j.tips.2021.01.003
Prieto Martínez FD, Arciniega M, Medina Franco JL. Molecular docking: current advances and challenges. TIP [Internet]. 2018 [cited 25/12/2022];21(1):65–87. Available from: https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405- 888X2018000321108
Delavan B, Roberts R, Huang R, Bao W, Tong W, Liu Z. Computational drug repositioning for rare diseases in the era of precision medicine. Drug Discov Today. [Internet]. 2018 [cited 25/12/2022];23(2):382–94. Available from: https://doi.org/10.1016/j.drudis.2017.10.009
Bhattacharya S, Das MK, Sarkar S, De A. Hematidrosis. Indian Pediatrics. [Internet]. 2013 [cited 07/01/2023];50:703–704. Available from: https://link.springer.com/content/pdf/10.1007/s13312-013-0178-x.pdf
Chua KP, Conti RM. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19. JAMA Intern Med [Internet]. 2020 [cited 10/02/2023];180(10):1273–4. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2769375
Postema PG, Schwartz PJ, Arbelo E, Bannenberg WJ, Behr ER, Belhassen B, et al. Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. Eur Heart J [Internet]. 2020 [cited 11/02/2023];41(5):614–7. Available from: https://doi.org/10.1093/eurheartj/ehaa041
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
La revista está: Certificada por el CITMA
La revista es de acceso abierto y gratuito.